Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuron (IMRN) Other Working Capital Changes (2020 - 2023)

Immuron's quarterly Other Working Capital Changes came in at -$1.7 million in Q2 2023, up 23.07% year-on-year from -$1.4 million in Q2 2022, and up 23.07% quarter-over-quarter from -$2.3 million in Q2 2022.

Immuron has reported Other Working Capital Changes for 4 years, with the latest figure at -$1.7 million in Q2 2023.

  • For the quarter ending Q2 2023, Other Working Capital Changes rose 23.07% year-over-year to -$1.7 million; the trailing twelve-month figure through Jun 2023 stood at -$9.2 million (changed N/A YoY), and the FY2023 full-year result was -$1.7 million, up 23.07% from the prior year.
  • Other Working Capital Changes for Q2 2023 stood at -$1.7 million, up from -$2.3 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was -$1.7 million in Q2 2023, with the low at -$3.1 million in Q2 2021.
  • Average Other Working Capital Changes over 4 years is -$2.3 million, with a median of -$2.2 million recorded in 2022.
  • Year-over-year, Other Working Capital Changes slumped 52.26% in 2021 and climbed 28.22% in 2022.
  • Tracing IMRN's Other Working Capital Changes over 4 years: stood at -$2.1 million in 2020, then plunged by 52.26% to -$3.1 million in 2021, then increased by 28.22% to -$2.3 million in 2022, then advanced by 23.07% to -$1.7 million in 2023.
  • The last three Other Working Capital Changes figures came in at -$1.7 million (Q2 2023), -$2.3 million (Q2 2022), and -$3.1 million (Q2 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Immuron 1.27 Bn 1.27 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 -1.73 Mn
Jun 30, 2023 -1.73 Mn
Jun 30, 2022 -2.25 Mn
Jun 30, 2022 -2.25 Mn
Jun 30, 2021 -3.14 Mn
Jun 30, 2021 -3.14 Mn
Jun 30, 2020 -2.06 Mn
Jun 30, 2020 -2.06 Mn